Evolus expands Symatese pact to add Canada, Australia, New Zealand for Estyme

Evolus, Inc. disclosed in an 8-K that on August 3, 2026 its subsidiary Evolus Pharma B.V. signed an amendment to its existing license, supply and distribution agreement with Symatese Aesthetics S.A.S., originally dated December 20, 2023. The amendment extends the deal's territory to Canada plus a combined Australia and New Zealand region, giving Evolus Europe sole rights to sell and distribute Symatese's complete Estyme-branded hyaluronic acid gel line there.¹

On payment terms, Evolus Europe must pay €920,000 upfront, with up to another €1.38 million due if certain regulatory approvals are reached.¹ Symatese will cover, at its own cost, the development and regulatory work needed to win and keep approvals in the new territories.¹ Each new territory carries a 15-year initial term starting from the first regulatory approval there, renewing automatically in five-year increments under the agreement's conditions.¹

The company's press release said the deal rounds out its injectable portfolio. With the addition, Evolus said it will hold exclusive commercialization rights for its HA gel line in every market where it already sells Jeuveau and Nuceiva, once commercialization begins in 2028.¹ Evolus estimated the combined neurotoxin and filler markets in these three countries at roughly $500 million a year, split about 60% neurotoxins and 40% dermal fillers.¹

On the commercial split, Symatese keeps responsibility for product development, manufacturing, clinical support, and the regulatory work needed to secure and maintain marketing approvals in the licensed territories.¹ Evolus will buy product from Symatese at an agreed transfer price and pay a mid-single digit royalty on net sales.¹ The amendment itself will be filed as an exhibit with Evolus's next 10-Q, covering the quarter ending September 30, 2026.